soul trial oral semaglutide Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo The SOUL Trial | Otavio
Description
Understanding individual risk factors, biomarker patterns, and mitigation strategies can help patients and providers optimize treatment tolerability
These are the conclusions of an observational study published in Nature Medicine
Explore alternatives and FAQs.
Learn how these weight loss medications differ in mechanism, dosing, results, and which may suit you best.
